Akero Therapeutics Announces Pricing of Public Offering

On January 28, 2025, Akero Therapeutics, Inc. (NASDAQ: AKRO) disclosed in an 8-K filing that it has entered into an underwriting agreement with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, and Jefferies LLC. The agreement involves the issuance and sale of 5,333,420 common shares of the company at a public offering price of […]

Leave a Reply

Your email address will not be published.

Previous post Heritage Financial Services LLC Makes New $557,000 Investment in Vanguard Value ETF (NYSEARCA:VTV)
Next post Akero Therapeutics Announces Pricing of Public Offering